Navigation Links
Transition in cell type parallels treatment response, disease progression in breast cancer
Date:1/31/2013

and triple-negative tumors the assay revealed a small number of epithelial cells that also expressed mesenchymal markers. The investigators then conducted EMT analysis of circulating tumors cells (CTCs) cells that break off from solid tumors and travel through the bloodstream using the second-generation CTC-chip device developed in collaboration with the MGH Center for Engineering in Medicine.

Analysis of blood samples from 41 patients with metastatic breast cancer at various stages of their treatment identified CTCs expressing mesenchymal markers (M+) in samples from 16 patients. Pre- and post-treatment samples were available from 10 patients, 5 who had responded to treatment and 5 who had not. While post-treatment samples from patients whose tumors responded showed either an overall drop in the number of CTCs captured or fewer M+ cells, samples from patients whose tumors did not respond showed an increased proportion of M+ CTCs.

The investigators had access to serial blood samples taken from one patient at various stages during the course of her disease, which included initial response to an experimental treatment, followed by treatment resistance, subsequent response to another protocol and then resumed tumor progression. Both the number of CTCs and the proportion of cells with mesenchymal markers to those with epithelial markers dropped when her tumor responded to treatment and then rose when the disease progressed. The researchers also observed that an increase in M+ CTCs in this patient was associated with the appearance of multicellular clusters of CTCs, which conflicts with the predominant model of EMT inducing single tumor cells to migrate into the bloodstream, and they found evidence that the growth factor TGF-beta may mediate EMT in cancer.

"This study provides us with a new biologic understanding of breast cancer invasion and metastasis," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and co-correspo
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Topological transitions in metamaterials
2. Study Shows Transition to Practice Programs Get Nurses Employed
3. Innosight Announces Leadership Transition
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
6. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
7. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
8. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
9. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
10. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
11. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... , DARTMOUTH, NS , July 12 /PRNewswire/ - ... Omega-3, EPA/DHA, food and dietary supplement ingredients, announces today the acquisition ... Essentials (GAT) Omega-3 microencapsulation-emulsion technology. , ... As a result of the agreement, ONC acquired ...
... July 12, 2010 Points to,Novel Pathway for Drug Discovery, ... Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic colleagues ... and North America today,report the discovery of a common single-letter ...
... , , ... Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing ... clinical advisory panel (the "Panel"). , , ... Panel of international experts with special expertise in ovarian cancer has been charted ...
Cached Biology Technology:Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 2Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4Quest PharmaTech Announces Formation of Clinical Advisory Panel 2Quest PharmaTech Announces Formation of Clinical Advisory Panel 3
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... types are essential for studies of their development ... A Laboratory Manual provides step-by-step protocols for isolating ... them under conditions that closely resemble those in ... dissect the brain, spinal cord, and other tissues; ...
... Did you know that crystals form the basis for the penetrating ... the future in solar energy technology? Crystals are at the ... formed naturally, but manufactured to form alloys, such as indium gallium ... LEDs, for illumination in the visible range, and of laser diodes ...
... grams of essential amino acids taken twice daily for a week ... mean age 69, recover faster and with much less muscle atrophy ... detailed in a paper now online ahead of print in the ... -- could spell relief and speed recovery for a growing population ...
Cached Biology News:ASU, Georgia Tech create breakthrough for solar cell efficiency 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: